The processing and subsequent presentation of the tumor antigens released by the dead cells would allow the activation of CD8+ T cells lymphocytes by cross-priming mechanisms (104), which would ultimately attack the BCSC resistance to chemotherapy (Figure 1A). This evidence concerns the gene CD8A and neoplasm.